News Sentiment

UTHR sentiment intelligence

United Therapeutics Corporation news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 64 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 547.06 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

83/100 classification confidence.

Company focus 64

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

-1.6% over one week, +0.2% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Is United Therapeutics a "Quant King" Favorite for a Reason

Market Reaction

Balanced read

67/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 83/100 classification
One-week reaction -1.6% Price digesting
Trend fit Trend active 0.2% over four weeks
Fair value 56.2% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 24
Neutral 37
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 64
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Market source 8
Investing.com Canada 7
Investing.com 6
Moomoo 4
MT Newswires 4
Quartr 4
simplywall.st 4
Stock Titan 3

Event Lens

What the news is about

Classified themes
Market update 42
Earnings 6
Deals and strategy 6
Regulatory and legal 5
Balance sheet 4
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 64
Investing.com Canada Direct company coverage

Form 4 United Therapeutics Corporation For: 13 July By Investing.com

This article from Investing.com reports on a Form 4 filing for United Therapeutics Corporation related to July 13th. Form 4 filings typically disclose changes in beneficial ownership of a company's securities by officers, directors, or significant shareholders. The article is bri

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 21:10
Source
Investing.com Canada
Stock Titan Direct company coverage

[Form 4] UNITED THERAPEUTICS Corp Insider Trading Activity

Martine A. Rothblatt, Chairperson & CEO of UNITED THERAPEUTICS Corp, reported insider trading activity on July 10, 2026. She exercised 9,500 stock options at $135.42 per share and subsequently sold 9,500 shares of Common Stock in multiple open-market transactions, ranging from $5

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 20:41
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 144 UNITED THERAPEUTICS CORPORATION For: 10 July By Investing.com

This article announces the filing of Form 144 for UNITED THERAPEUTICS CORPORATION on July 10. Such filings typically report insider intent to sell restricted stock. The content provides basic information about the filing without further details on the transaction itself.

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 20:40
Source
Investing.com Canada
Investing.com Canada Direct company coverage

Form 4 United Therapeutics Corporation For: 10 July By Investing.com

This article provides details of a Form 4 filing for United Therapeutics Corporation on July 10. Form 4 filings are regulatory documents indicating changes in beneficial ownership of securities by company insiders. The publication comes from Investing.com.

Tone
Neutral 50/100
Event
Regulatory and legal
Published
10 Jul 2026 20:40
Source
Investing.com Canada
Investing.com Canada Direct company coverage

United Therapeutics director Jan Malcolm sells $178,941 in stock By Investing.com

United Therapeutics Corp director Jan Malcolm sold 325 shares of the company's stock for $178,941 on July 10, 2026, following the vesting of restricted stock units. The transaction was executed under a pre-arranged 10b5-1 plan established in September 2025. United Therapeutics ha

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 20:39
Source
Investing.com Canada
Investing.com Direct company coverage

United Therapeutics director Jan Malcolm sells $178,941 in stock

United Therapeutics director Jan Malcolm sold 325 shares of company stock worth $178,941 on July 10, 2026, following the vesting of restricted stock units. The sale was executed under a pre-arranged 10b5-1 plan. Despite the sale, the company maintains a "GREAT" financial health s

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 04:07
Source
Investing.com
Investing.com Nigeria Direct company coverage

United Therapeutics CEO Martine Rothblatt sells $5.2m shares By Investing.com

Martine A. Rothblatt, CEO of United Therapeutics Corp, sold approximately $5.24 million worth of common stock on July 9, 2026. This transaction followed the exercise of stock options and was executed under a pre-arranged 10b5-1 trading plan. The article also mentions the company'

Tone
Negative 37/100
Event
Market update
Published
10 Jul 2026 01:11
Source
Investing.com Nigeria
Investing.com Canada Direct company coverage

Martine Rothblatt, United Therapeutics chairperson & CEO, sells $5.25m By Investing.com

Martine Rothblatt, Chairperson and CEO of United Therapeutics Corp, recently sold over $5.25 million in company stock after exercising options valued at $1.28 million. These transactions, executed under a pre-arranged 10b5-1 trading plan, highlight significant insider activity fo

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 21:05
Source
Investing.com Canada
TradingView Direct company coverage

United Therapeutics Stock Rises 14% YTD: Here's What You Need to Know

United Therapeutics (UTHR) stock has risen 14% year-to-date due to clinical breakthroughs and improved long-term growth visibility. The company is expanding its nebulized Tyvaso into larger pulmonary fibrosis markets and has successful late-stage pipeline candidates like ralinepa

Tone
Positive 82/100
Event
Market update
Published
09 Jul 2026 18:05
Source
TradingView
Quartr Direct company coverage

United Therapeutics (UTHR) Q1 2026 earnings summary

United Therapeutics (UTHR) reported Q1 2026 revenues of $781.5–$782 million, a 2% year-over-year decrease, with net income falling 15% to $274.9 million. Despite overall revenue decline, Orenitram sales reached a record high, and Tyvaso DPI sales increased by 9%. The company anti

Tone
Positive 64/100
Event
Earnings
Published
09 Jul 2026 06:40
Source
Quartr
Quartr Direct company coverage

United Therapeutics (UTHR) Proxy filing Summary

United Therapeutics (UTHR) has released its proxy filing summary for the upcoming annual meeting on June 26, 2026. Shareholders will vote on director elections, executive compensation, a new stock incentive plan, and auditor ratification. The company reported 11% revenue growth a

Tone
Positive 72/100
Event
Earnings
Published
09 Jul 2026 05:05
Source
Quartr
Quartr Direct company coverage

United Therapeutics (UTHR) Q2 2025 earnings summary

United Therapeutics (UTHR) reported record total revenue of $799 million for Q2 2025, a 12% year-over-year increase, marking 12 consecutive quarters of double-digit growth driven by products like Tyvaso DPI, Nebulized Tyvaso, Orenitram, and Unituxin. The company's board authorize

Tone
Positive 71/100
Event
Earnings
Published
09 Jul 2026 04:05
Source
Quartr
Quartr Direct company coverage

United Therapeutics (UTHR) Study result Summary

United Therapeutics (UTHR) announced the results of its Phase III ADVANCE OUTCOMES study for ralinepag in patients with Pulmonary Arterial Hypertension (PAH). The study showed that ralinepag significantly reduced the risk of clinical worsening events by 55% compared to placebo, w

Tone
Positive 70/100
Event
Earnings
Published
09 Jul 2026 03:40
Source
Quartr
Investing.com Canada Direct company coverage

Form 4 United Therapeutics Corporation For: 8 July By Investing.com

This article announces the filing of Form 4 for United Therapeutics Corporation on July 8th. Form 4 reports changes in beneficial ownership of company stock by insiders. The article provides no further details beyond this announcement.

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 20:40
Source
Investing.com Canada
Investing.com Canada Direct company coverage

United Therapeutics CEO Martine Rothblatt sells $5.3m company stock By Investing.com

United Therapeutics CEO Martine Rothblatt sold 9,500 shares of the company's common stock for approximately $5.31 million after exercising stock options worth $1.29 million. These transactions were conducted under a pre-arranged 10b5-1 trading plan. The company's shares have rise

Tone
Negative 40/100
Event
Market update
Published
08 Jul 2026 20:39
Source
Investing.com Canada
BioBuzz Direct company coverage

United Therapeutics expands immune therapy pipeline with Thymmune

United Therapeutics (UTHR) has acquired Thymmune Therapeutics for $140 million in cash and potential earn-out payments of up to $160 million. Thymmune specializes in preclinical regenerative thymic cell therapies aimed at restoring immune function and improving transplant outcome

Tone
Positive 71/100
Event
Balance sheet
Published
08 Jul 2026 14:39
Source
BioBuzz